Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

Executive Summary

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

You may also be interested in...



EVAR Update: Companies Target Complex Anatomies With Innovative Solutions

As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.

Cordis Launches Low-Profile Incraft AAA Stent Graft In Europe And Canada

The J&J division has been talking-up Incraft as a potentially major innovation in the treatment abdominal aortic aneurysms for several years.

Endologix Hopes Nellix Deal Is A Winning Hand

AAA company Endologix Inc. is carving a niche for itself in the crowded endovascular aneurysm repair field with two new products. It has developed a method of delivering aortic aneurysm grafts through a percutaneous opening, but the company’s larger opportunity might lie in a piece of technology acquired three years ago – the Nellix Endovascular Aneurysm Sealing system.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel